CorMatrix ECM Technology
CorMatrix ECM Technology has been used at more than 825 hospitals across the U.S. and has been implanted in nearly 95,000 cardiac procedures. This naturally occurring extracellular matrix biomaterial supports native tissue repair by providing an interim bioscaffold, that enables a patient's own cells to repopulate and repair damaged tissues.
CorMatrix® Cardiovascular, Inc. is a privately held medical device company dedicated to developing and delivering innovative biomaterial devices that harness the body’s own innate ability to repair damaged heart tissue. The Company is currently researching, developing and commercializing a platform technology, known as CorMatrix ECM®, for a variety of cardiovascular indications.
CorMatrix is currently conducting a number of preclinical and clinical studies utilizing its ECM Technology for a variety of cardiovascular applications. An emulsified form of CorMatrix ECM is currently in preclinical testing to assess the impact the technology may have on reversing cardiac damage resulting from a heart attack or congestive heart failure and potentially improving overall heart function.